Member Info for BuenaVista

Not a valid assumption:

RNS of 31 March 2026: https://www.lse.co.uk/rns/AVCT/first-patient-treated-in-phase-1-trial-of-ava6103-y8dw94kz9edk9xv.html

"The first three centers open for enrollment in the FOCUS-01 study are the Virginia Cancer Specialists (VCS) Research Institute in Fairfax, Virgina, NEXT Oncology Specialists in Dallas, Texas, and START Midwest Center for Oncology Research in Grand Rapids Michigan. Further information on the study can be found on clinicaltrials.gov, under study number NCT07454642."

The Grand Rapids site has been there since FPD, it's just that the ClinicalTrials record didn't get updated until this week.

Either that or he thinks he's Austin Powers

Study status — Primary Completion changed from 15 March 2026 (estimated) to 15 June 2026 (estimated) with Study Completion unchanged at 15 August 2026 (estimated).

😂 You're probably too young to remember computer systems (looking at you VAX!) that took some 15 seconds to respond to input so all the keys that you pressed in frustration-cum-desperation-cum-hope whilst waiting for the first to execute would be stored up and executed in sequence on the then current page, sending you in the end to a completely unexpected and undesired part of the system!

The only thing Synairgen can be compared to is a dog. Holgate was hawking it around well before I retired, which was many moons ago – SNG001 (the one and only)😂 ...a therapy without a disease.

Wrong thread. Mobile/WiFi being very glitchy.

The only thing Synairgen can be compared to is a dog. Holgate was hawking it around well before I retired, which was many moons ago. SNG001 (the one and only)😂 ...a therapy without a disease.

Yes, as per yesterday's RNS: "As a result of the Conversion, the principal remaining under the convertible bond will be reduced by £1.20 million to £19.20 million."

The February 2021 dilution: https://www.lse.co.uk/rns/AVCT/affyxell-73-million-series-a-financing-0n90z8vwqwebdjn.html (1 February 2021)

"AffyXell $7.3 Million Series A Financing

"......

"Under the terms of the collaboration and licence agreement, Avacta's research and development costs associated with the generation of the Affimer proteins are funded by AffyXell whilst Avacta retains the rights to commercialise the Affimer proteins outside the field of cell therapies.

"......"

- - - - -

The joint venture: https://www.lse.co.uk/rns/AVCT/avacta-and-daewoong-establish-joint-venture-svhid8xoh5e2w7b.html (8 January 2020)

"Avacta and Daewoong Establish Joint Venture

"......"

"Daewoong will provide the joint venture with access to its proprietary technology for generating allogeneic MSCs from a single donor to treat a large number of patients. This proprietary technology facilitates the development of cell therapies as "off-the-shelf" products.

"Avacta's shareholding in the joint venture is 45%. The joint venture will be operationally managed by Seng-ho Jeon, CEO of Daewoong, with a Board composed of representatives of both Avacta (Alastair Smith, CEO and Matthew Vincent, VP Business Development and Strategy) and Daewoong.

"......"

^ between 21% and 25%

Pick a number between 22% and 25%! Avacta are remarkably quiet about this venture. The last mention was in the Preliminary Results for the Year Ended December 31, 2024 RNS on 6 June 2025: https://avacta.com/preliminary-results-for-the-year-ended-december-31-2024/

"The Group investment [in AffyXell Therapeutics] decreased from 25% to 21% at 31 December 2024 as a result of a dilution in shares."

- - - - -

Background: https://avacta.com/affyxell-joint-venture-milestone-and-increased-equity-stake/ (13 April 2022)

"AffyXell joint venture milestone and increased equity stake

"Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, is pleased to announce that a milestone equity payment has been triggered resulting in an increase in Avacta’s shareholding in AffyXell Therapeutics (“AffyXell”), a joint venture between Avacta and Daewoong Pharmaceutical (“Daewoong”) in South Korea.

"Avacta has successfully developed and characterised Affimer® proteins against the first target for AffyXell and has now transferred intellectual property relating to Affimer® proteins against that target into AffyXell, triggering an agreed milestone in the joint venture agreement. In exchange for this, Avacta has received an increase in its equity stake in AffyXell, which was diluted from its founding equity stake in February 2021 when AffyXell completed a Series A financing of $7.3 million from a group of venture funds in February 2021. Avacta’s shareholding in the joint venture now stands at 22%.

"AffyXell was established in January 2020 by Avacta and Daewoong as a joint venture to develop novel mesenchymal stem cell (“MSC”) therapies. AffyXell is combining Avacta’s Affimer® platform with Daewoong’s MSC platform such that the stem cells are genetically modified to produce and secrete therapeutic Affimer® proteins with immuno-modulatory effects in situ in the patient. The Affimer® proteins are designed to enhance the therapeutic effects of the MSC creating a novel, next generation cell therapy platform."

- - - - -

AI summary:

• February 2021: Avacta's founding stake was diluted following a $7.3 million Series A financing round

• April 2022: The stake rose to 22% after the first development milestone was met

• June 2023: Avacta announced a second milestone, which eventually led to the stake increasing further toward 25%

• December 2024: The stake was reported to have diluted back to 21%

• Current (May 2026): Avacta's holding is approximately 25% as the venture prepares for an IPO

- - - - -

NOTE: I couldn't find a definite reference to a current 25% holding and Gemini didn't provide one amongst the given sources.

Heights did this once before, back in February 2023. It's clearly not been excluded in the renegotiated agreement.

https://www.lse.co.uk/rns/AVCT/issue-of-equity-and-total-voting-rights-5bljh0vsiis0xse.html

"if there were any adverse events I think they would have been reported by now"

There have clearly been no trial-stopping adverse events as the management are just exuding confidence. Hopefully there will have been no minor side effects either, but time will tell (us).

He's just angry cos he was out at 75p and now the offy didn't have any of his favourite tipple.

Filter the ones that always seem to engage as well and the board becomes quite readable.

The video of the 2024 R&D Spotlight (6) on Science Day recording on 30 October was put on the Avacta website on 8 November.

https://avacta.com/video-presentations-from-rd-spotlight-next-generation-of-precision-medicines/

What BBs did our former friend used to post on?

Petro Matad (MATD)?

Https://www.lse.co.uk/profiles/teabag66/

correct sb. ai is:

• very good for hard facts

• **** poor for interpretation

It literally doesn't matter how many thousands of words are squeezed out when they are all in my green bin.